Dr. Gonzalgo is a urologic oncologist with expertise in open and robotic surgical approaches for the treatment of prostate, bladder, and kidney cancers. He is a recognized expert in DNA methylation and is particularly interested in developing new diagnostic and therapeutic approaches for cancer detection and treatment. His research in understanding the molecular biology of cancer including research and patents in the methylation field have been used by laboratories around the world. He has served as PI, Co-I, and collaborator on grants from the NIH, DOD, various foundations, and industry. His mentorship of graduate students led to the founding of Gauss Surgical, a company (acquired by Stryker) focused on quantifying blood loss using the world’s first FDA-approved computer vision and machine learning platform for the operating room. Dr. Gonzalgo has been recognized as a Top Doctor by U.S. News & World Report and is an emeritus member.
Dr. Alan Yang is the Senior Vice President and Chief Medical Officer at Xencor. Dr. Yang joined Xencor as senior vice president and chief medical officer in December 2019. Previously he served as senior vice president, head of clinical development and acting chief medical officer at Jazz Pharmaceuticals. Before assuming this role at Jazz, Dr. Yang was the therapeutic area head for hematology and oncology, assembling its clinical development team and overseeing several oncology products, including Erwinaze®, Defitelio® and Vyxeos®. Prior to Jazz, Dr. Yang led clinical development and clinical operations groups at Spectrum Pharmaceuticals, where he was vice president of clinical research. Previously, he held several roles of increasing responsibility at Amgen, including those of global development leader for Aranesp® in oncology and clinical research medical director for Blincyto®, the first bispecific antibody approved by the FDA. Before transitioning to the biopharmaceutical industry, Dr. Yang practiced medicine for several years as an academic oncologist at the University of Southern California, where he led a translational cancer research laboratory. Dr. Yang earned a B.A. in molecular biology from the University of California, Berkeley, and a Ph.D. in biochemistry and an M.D. from the University of Southern California. He completed his medical oncology fellowship at the MD Anderson Cancer Center.